Phase I study of teclistamab, a humanized B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed/refractory multiple myeloma (R/R MM).

被引：34
作者：
Usmani, Saad Zafar
Mateos, Maria-Victoria
Nahi, Hareth
Krishnan, Amrita Y.
van de Donk, Niels W. C. J.
San Miguel, Jesus
Oriol, Albert
Rosinol, Laura
Chari, Ajai
Adams, Homer
Girgis, Suzette
Lin, Shun Xin Wang
Stephenson, Tara
Kemmerer, Kristy
Smit, Jennifer
Elsayed, Yusri A.
Infante, Jeffrey R.
Goldberg, Jenna D.
Banerjee, Arnob
Garfall, Alfred L.
机构：
[1] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA
[2] Univ Hosp Salamanca IBSAL, Salamanca, Spain
[3] Karolinska Inst, Stockholm, Sweden
[4] Karolinska Univ Hosp Huddinge, Stockholm, Sweden
[5] City Hope Natl Med Ctr, Duarte, CA USA
[6] Vrije Univ Amsterdam Med Ctr, Amsterdam Univ, Med Ctr, Amsterdam, Netherlands
[7] Clin Univ Navarra, Pamplona, Spain
[8] Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Badalona, Spain
[9] Hosp Badalona Germans Trias & Pujol, Inst Josep Carreras, Badalona, Spain
[10] Hosp Clin Barcelona, Barcelona, Spain
[11] Mt Sinai Sch Med, Dept Hematol Oncol, New York, NY USA
[12] Janssen Res & Dev LLC, Spring House, PA USA
[13] Janssen Res & Dev LLC, Raritan, NJ USA
[14] Perelman Sch Med, Philadelphia, PA USA
[15] Abramson Canc Ctr, Philadelphia, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
10.1200/JCO.2020.38.15_suppl.100
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
100
引用
收藏
页数：2
相关论文
共 50 条
[41]   Phase 1 study of talquetamab, a humanized GPRC5D x CD3 bispecific antibody, in Japanese patients with relapsed/refractory MM [J].
Iida, Shinsuke ;
Sunami, Kazutaka ;
Ito, Shigeki ;
Yuda, Junichiro ;
Fujikawa, Ei ;
Takamoto, Mikihiro ;
Aida, Kensuke ;
Yamazaki, Hiroshi ;
Takahashi, Marimo ;
Ishida, Tadao .
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2025,
[42]   Teclistamab and talquetamab modulate levels of soluble B-cell maturation antigen in patients with relapsed and/or refractory multiple myeloma. [J].
Girgis, Suzette ;
Xin, Shun ;
Lin, Wang ;
Pillarisetti, Kodandaram ;
Verona, Raluca ;
Vieyra, Diego ;
Casneuf, Tineke ;
Fink, Damien ;
Miao, Xin ;
Chen, Yang ;
Stephenson, Tara ;
Banerjee, Arnob ;
Hilder, Brandi ;
Russell, Jeffery Scott ;
Smit, Jennifer ;
Goldberg, Jenna D. .
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[43]   A Phase 1 First-in-Human Study of Abbv-383, a BCMA x CD3 Bispecific T-Cell-Redirecting Antibody, As Monotherapy in Patients with Relapsed/Refractory Multiple Myeloma [J].
Voorhees, Peter M. ;
D'Souza, Anita ;
Weisel, Katja ;
Hurd, David Duane ;
Teipel, Raphael ;
Chung, Alfred ;
Rodriguez, Cesar ;
Tuchman, Sascha A. ;
Korde, Neha ;
Safah, Hana ;
Bueno, Orlando F. ;
Pumford, Neil ;
Rosenberg, Tanya S. ;
Pothacamury, Rajvineeth Kumar ;
Ross, Jeremy A. ;
Polepally, Akshanth R. ;
Lee, Shane ;
Jin, Ziyi ;
Talati, Chetasi ;
Vij, Ravi ;
Kumar, Shaji K. .
BLOOD, 2022, 140 :4401-4404
[44]   Initial Results from a Phase 1 Study of TQB2934, a BCMA x CD3 Bispecific Antibody, As Monotherapy in Patients with Relapsed/Refractory Multiple [J].
Liu, Peng ;
Zhuang, Junling ;
Xia, Zhongjun ;
Li, Bingzong ;
Jiang, Songfu ;
Zhang, Yian ;
Wang, Wei ;
Chen, Xiaoqin ;
Zhang, Xiaohui ;
Zhou, Shujuan .
BLOOD, 2024, 144 :1998-1999
[45]   FDA Approval Summary: Teclistamab-A Bispecific CD3 T-Cell Engager for Patients with Relapsed or Refractory Multiple Myeloma [J].
Baines, Andrea C. ;
Kanapuru, Bindu ;
Zhao, Jay ;
Price, Lauren S. L. ;
Zheng, Nan ;
Konicki, Robyn ;
Manning, Michael L. ;
Gehrke, Brenda J. ;
Theoret, Marc R. ;
Gormley, Nicole J. .
CLINICAL CANCER RESEARCH, 2024, 30 (24) :5515-5520
[46]   Role of B-Cell Maturation Antigen (BCMA) Targeted Immunotherapies in Relapsed and Refractory Multiple Myeloma- a Systematic Review [J].
Shah, Zunairah ;
Batool, Syeda Sabeeka ;
Fazeel, Hafiz Muhammad ;
Malik, Mustafa Nadeem ;
Sadiq, Maryam ;
Hassan, Syeda Fatima ;
Syed, Tariq Iqtidar Sadiq ;
Abdullah, Syed Maaz ;
Javed, Nisma ;
Ashraf, Aqsa ;
Farooqui, Arafat Ali Ali ;
Yousaf, Muhammad Abdullah ;
Ahmad, Muhaddis Ejaz ;
Ghani, Marium ;
Akbar, Arshia ;
Anwer, Faiz .
BLOOD, 2019, 134
[47]   Modulation of soluble B-cell maturation antigen levels in patients with relapsed and/or refractory multiple myeloma after treatment with teclistamab and talquetamab [J].
Girgis, Suzette ;
Lin, Shun Xin Wang ;
Pillarisetti, Kodandaram ;
Verona, Raluca ;
Vieyra, Diego ;
Casneuf, Tineke ;
Fink, Damien ;
Miao, Xin ;
Chen, Yang ;
Stephenson, Tara ;
Banerjee, Arnob ;
Hilder, Brandi ;
Russell, Jeffery ;
Smit, Jennifer ;
Goldberg, Jenna .
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 :S39-S40
[48]   REGN5458, a BCMA x CD3 Bispecific Monoclonal Antibody, Induces Deep and Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) [J].
Madduri, Deepu ;
Rosko, Ashley ;
Brayer, Jason ;
Zonder, Jeffrey ;
Bensinger, William I. ;
Li, Jingjin ;
Xu, Linzhi ;
Adriaens, Lieve ;
Chokshi, Dhruti ;
Zhang, Weijiang ;
Boyapati, Anita ;
Sharma, Manish ;
Seebach, Frank ;
Sirulnik, L. Andres ;
Weinreich, David M. ;
Yancopoulos, George D. ;
Dhodapkar, Madhav V. ;
Lentzsch, Suzanne ;
Cooper, Dennis ;
Jagannath, Sundar .
BLOOD, 2020, 136
[49]   Talquetamab in B Cell Maturation Antigen (BCMA) Exposed Relapsed-Refractory Multiple Myeloma Patients [J].
Shaikh, Hira ;
Lochner, Jonathan ;
Loeffler, Bradley ;
Friend, Reed ;
Habib, Alma ;
Mckenna, Marshall ;
Snyder, Jordan ;
Davis, James A. ;
Patrus, Gina ;
Dileo, Rachel ;
Mewawalla, Prerna ;
Green, Kimberly M. ;
Mushtaq, Muhammad Umair ;
Strouse, Christopher ;
Tiger, Yun Kyoung ;
Abdallah, Al-Ola ;
Ahmed, Nausheen ;
Khan, Abdullah Mohammad ;
Hashmi, Hamza ;
Paul, Barry ;
Atrash, Shebli .
BLOOD, 2024, 144 :51704-51705
[50]   Updated results of a phase 1, first-in-human study of ABBV-383, a BCMA x CD3 bispecific T-cell redirecting antibody, in patients with relapsed/refractory multiple myeloma [J].
Voorhees, Peter ;
Shah, Nina ;
D'Souza, Anita ;
Rodriguez, Cesar ;
Weisel, Katja ;
Teipel, Raphael ;
Hurd, David ;
Bueno, Orlando ;
Pumford, Neil ;
Rosenberg, Tanya ;
Pothacamury, Rajvineeth Kumar ;
Ross, Jeremy ;
Polepally, Akshanth ;
Lee, Shane ;
Jin, Ziyi ;
Talati, Chetasi ;
Kumar, Shaji ;
Vij, Ravi .
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 :S34-S34
12345